KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Goodwill & Intangibles (2016 - 2026)

Biomarin Pharmaceutical has reported Goodwill & Intangibles over the past 18 years, most recently at $400.9 million for Q1 2026.

  • For the quarter ending Q1 2026, Goodwill & Intangibles fell 9.62% year-over-year to $400.9 million, compared with a TTM value of $400.9 million through Mar 2026, down 9.62%, and an annual FY2025 reading of $410.0 million, down 9.18% over the prior year.
  • Goodwill & Intangibles came in at $400.9 million for Q1 2026, down from $410.0 million in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $570.4 million in Q1 2022 to a low of $400.9 million in Q1 2026.
  • Median Goodwill & Intangibles over the past 5 years was $475.9 million (2024), compared with a mean of $482.7 million.
  • The sharpest move saw Goodwill & Intangibles fell 4.22% in 2022, then fell 10.44% in 2023.
  • Over 5 years, Goodwill & Intangibles stood at $534.8 million in 2022, then fell by 8.2% to $490.9 million in 2023, then fell by 8.03% to $451.5 million in 2024, then fell by 9.18% to $410.0 million in 2025, then fell by 2.24% to $400.9 million in 2026.
  • Per Business Quant, the three most recent readings for BMRN's Goodwill & Intangibles are $400.9 million (Q1 2026), $410.0 million (Q4 2025), and $429.3 million (Q3 2025).